Marker Therapeutics to Raise $16.1 Million in Private Placement

MT Newswires Live12-20

Marker Therapeutics (MRKR) said Thursday it has agreed to sell securities worth $16.1 million to investors including Blue Owl Healthcare Opportunities (OWL), New Enterprise Associates and Aisling Capital in a private placement.

Marker said it will sell about 5 million shares, or pre-funded warrants, and warrants to buy up to around 5 million shares at a price of $3.20 per share and accompanying warrant.

Net proceeds will be allocated toward supporting the phase 1 Apollo trial studying the company's multi-antigen recognizing T cell product, it added.

The company's shares were down 4.2% in recent trading.

Price: 3.81, Change: -0.22, Percent Change: -5.46

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492104533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 01:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492104533","market":"us","top_or_hot":-1,"title":"Marker Therapeutics to Raise $16.1 Million in Private Placement","media":"MT Newswires Live","content":"<html><body><p> Marker <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (MRKR) said Thursday it has agreed to sell securities worth $16.1 million to investors including Blue Owl Healthcare Opportunities (OWL), New Enterprise Associates and Aisling Capital in a private placement.</p><p>Marker said it will sell about 5 million shares, or pre-funded warrants, and warrants to buy up to around 5 million shares at a price of $3.20 per share and accompanying warrant.</p><p>Net proceeds will be allocated toward supporting the phase 1 Apollo trial studying the company's multi-antigen recognizing T cell product, it added.</p><p>The company's shares were down 4.2% in recent trading.</p><p>Price: 3.81, Change: -0.22, Percent Change: -5.46</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Marker Therapeutics to Raise $16.1 Million in Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarker Therapeutics to Raise $16.1 Million in Private Placement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 01:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Marker Therapeutics (MRKR) said Thursday it has agreed to sell securities worth $16.1 million to investors including Blue Owl Healthcare Opportunities (OWL), New Enterprise Associates and Aisling ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4135","symbol_name":"资产管理与托管银行","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492104533","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492104533","pubTimestamp":1734629905,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Marker Therapeutics  said Thursday it has agreed to sell securities worth $16.1 million to investors including Blue Owl Healthcare Opportunities , New Enterprise Associates and Aisling Capital in a private placement.Marker said it will sell about 5 million shares, or pre-funded warrants, and warrants to buy up to around 5 million shares at a price of $3.20 per share and accompanying warrant.Net proceeds will be allocated toward supporting the phase 1 Apollo trial studying the company's multi-antigen recognizing T cell product, it added.The company's shares were down 4.2% in recent trading.Price: 3.81, Change: -0.22, Percent Change: -5.46","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4135":"资产管理与托管银行","MRKR":"Marker Therapeutics, Inc.","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LENZ":"Therapeutics","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","OWL":"Blue Owl Capital Inc.","BK4139":"生物科技","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC"},"translate_title":"Marker Therapeutics将通过私募筹集1610万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"MRKR":0.9,"OWL":0.9},"content_text":"Marker Therapeutics (MRKR) said Thursday it has agreed to sell securities worth $16.1 million to investors including Blue Owl Healthcare Opportunities (OWL), New Enterprise Associates and Aisling Capital in a private placement.Marker said it will sell about 5 million shares, or pre-funded warrants, and warrants to buy up to around 5 million shares at a price of $3.20 per share and accompanying warrant.Net proceeds will be allocated toward supporting the phase 1 Apollo trial studying the company's multi-antigen recognizing T cell product, it added.The company's shares were down 4.2% in recent trading.Price: 3.81, Change: -0.22, Percent Change: -5.46","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492104533"}